Joint-Wit Medical & Pharmaceutical Industry And SU BioMedicine To Set Up Joint Venture
This article was originally published in PharmAsia News
Sichuan Joint-Wit Medical & Pharmaceutical Industry and Netherlands-based SU BioMedicine will each invest RMB 5 million to set up a 50:50 joint venture, which will operate businesses such as herbal medicine, TCM, food additive R&D, marketing, as well as Chinese medicine intermediates production. SU BioMedicine, a subsidiary of the Netherlands Organization for Applied Scientific Research, currently collaborates with many Chinese research institutions and enterprises to develop plant medicine for metabolism syndrome. The tie-up will improve Joint-Wit's international competitiveness through the introduction of advanced pharmaceutical techniques. The joint company will establish a GMP-compliant production line within existing Joint-Wit facilities to produce plant medicine and food addictives, to be developed into plant or natural medicine for the EU and U.S. markets. (Click here for more - Chinese Language)
You may also be interested in...
Royal Philips will make 43,000 medical ventilators by year-end for use in the US and make 2,500 more for the Strategic National Stockpile in a deal with the US government worth $646.7m. See what Philips’ CEO Frans van Houten said about it here.
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.